UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 18, 2005
SCICLONE PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware | 0-19825 | 94-3116852 |
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer) Identification No.) |
| | |
901 Mariner’s Island Blvd., Suite 205
San Mateo, California 94404
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (650) 358-3456
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
0 Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
0 Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
0 Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
0 Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01. Entry into a Material Definitive Agreement.
The Board of Directors (the “Board”) of SciClone Pharmaceuticals, Inc. (the “Company”) has approved a $90,000 bonus for fiscal year 2004 for Hans P. Schmid, the Managing Director of SciClone Pharmaceuticals International, Ltd., and a $17,570 increase in Mr. Schmid’s annual salary, from $251,000 for fiscal year 2004 to $268,570 for fiscal year 2005, beginning as of January 1, 2005. The Board’s approval of such bonus and salary increase became effective as of February 14, 2005.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
SCICLONE PHARMACEUTICALS, INC. |
| |
Dated: February 18, 2005 | /s/ Richard A. Waldron |
| Richard A. Waldron |
| Chief Financial Officer |
| |
